Evidence map›Paper›PMID 38250665›Full record

ArticleAIChE journal. American Institute of Chemical Engineers2023

Engineering a drug eluting ocular patch for delivery and sustained release of anti-inflammatory therapeutics.

Xi Chen, Shima Gholizadeh, Mahsa Ghovvati, Ziqing Wang, Marcus J Jellen, Azadeh Mostafavi, Reza Dana, Nasim Annabi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIChE journal. American Institute of Chemical Engineers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xi ChenDepartment of Chemical and Biomolecular Engineering, University of California- Los Angeles, Los Angeles, CA, USA.
Shima GholizadehDepartment of Chemical and Biomolecular Engineering, University of California- Los Angeles, Los Angeles, CA, USA.
Mahsa GhovvatiDepartment of Chemical and Biomolecular Engineering, University of California- Los Angeles, Los Angeles, CA, USA.
Ziqing WangDepartment of Chemical and Biomolecular Engineering, University of California- Los Angeles, Los Angeles, CA, USA.
Marcus J JellenDepartment of Chemistry and Biochemistry, University of California- Los Angeles, Los Angeles, CA, USA.
Azadeh MostafaviDepartment of Chemical and Biomolecular Engineering, University of California- Los Angeles, Los Angeles, CA, USA.
Reza DanaSchepens Eye Research Institute, Mass Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Nasim AnnabiDepartment of Chemical and Biomolecular Engineering, University of California- Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USMassachusetts Eye and Ear Infirmary · US

Funding

Engineering highly elastic surgical sealants with hemostatic propertiesR01HL140618 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANNABI, NASIM, KHADEMHOSSEINI, ALI · 2018 to 2021
$2.8M
Engineering a naturally derived and highly adhesive surgical sealantR01EB023052 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANNABI, NASIM, KHADEMHOSSEINI, ALI · 2017 to 2022
$2.4M
NHLBI NIH HHS R01 HL140618NIBIB NIH HHS R01 EB023052
6 · The paper itself

Abstract

Ocular inflammation is commonly associated with eye disease or injury. Effective and sustained ocular delivery of therapeutics remains a challenge due to the eye physiology and structural barriers. Herein, we engineered a photocrosslinkable adhesive patch (GelPatch) incorporated with micelles (MCs) loaded with Loteprednol etabonate (LE) for delivery and sustained release of drug. The engineered drug loaded adhesive hydrogel, with controlled physical properties, provided a matrix with high adhesion to the ocular surfaces. The incorporation of MCs within the GelPatch enabled solubilization of LE and its sustained release within 15 days.

Identifiers

PMID38250665
PMCPMC10798673
OpenAlexW4319786215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.